What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible? The personalized biotech revolution turns raw genetic information into tailored treatments that actually work for each patient.
Grand View Research pegs the global precision medicine market growing at a 16.3% compound annual growth rate till 2030 when it reaches $249.24 billion. Two stocks deliver the full picture: one reads the genome at industrial scale, the other edits it with precision. Smart investors who want both sides of the equation already own Illumina (NASDAQ:ILMN) and CRISPR Therapeutics. (NASDAQ:CRSP)
Cathie Wood Spotted This Flywheel Years Ago
Cathie Wood has flagged genomics as a multi-decade megatrend in every ARK Big Ideas report since the late 2010s. She sees sequencing and gene editing as two halves of the same revolution — data first, cures second. Her conviction shows up in the numbers.
Her ARK Genomic Revolution ETF (CBOE:ARKK) shows CRISPR ranking as the top holding at 9.29% of assets while ILMN sits at 4.44%. That’s more than double the weight for the editor over the sequencer, yet both remain core positions. Wood has been adding to CRISPR in recent weeks, including $7.7 million worth across the Genomic Revolution and ARK Innovation ETF (CBOE:ARKK) on March 12 and 13 alone. And while Wood was a buyer of Illumina throughout 2025, she has been selling down her position in both ETFs in 2026.
Still, she treats the pair as essential infrastructure for personalized medicine.
Illumina: The Read That Feeds the Revolution
Illumina doesn’t sell therapies. It sells the high-throughput sequencers and consumables that generate the genetic data everything else runs on. In its fourth quarter earnings release, the company reported revenue of $1.16 billion, up 5% year-over-year. Outside of China, revenue rose 8%. Sequencing consumables alone reached $755 million, up 8%. Full-year 2025 revenue totaled $4.34 billion — flat overall but with ex-China growth of 2%.
For 2026, the company guided revenue of $4.5 billion to $4.6 billion, or 4% to 6% growth, including a 1.5% to 2% lift from the SomaLogic acquisition that expands multi-omics capabilities.
That installed base and recurring consumables revenue give Illumina a moat Thermo Fisher Scientific (NYSE:TMO) and Pacific Biosciences (NASDAQ:PACB) can’t match in clinical volume. The January launch of the Billion Cell Atlas — scaling to five billion cells — now trains AI models for Merck (NYSE:MRK | MRK Price Prediction), AstraZeneca (NYSE:AZN), and Eli Lilly (NYSE:LLY).
In short, Illumina supplies the raw material that makes every downstream therapy smarter.
CRISPR Therapeutics: The Edit That Delivers the Cure
CRISPR Therapeutics takes the genetic map Illumina helps draw and rewrites the faulty instructions. Its lead product, CASGEVY (developed with Vertex (NASDAQ:VRTX)), generated $116 million in revenue in 2025 — including $54 million in Q4.. That reflects 64 patients infused and 147 who began the treatment process, nearly three times the prior year. Pediatric submissions start in the first half of 2026.
The rest of the pipeline — zugo-cel in oncology and autoimmune, in vivo liver programs like CTX310 and CTX340, plus siRNA and regenerative candidates — extends the platform into cardiovascular disease, clotting disorders, and rare conditions.
While Illumina provides the diagnostic foundation, CRISPR turns those insights into one-time, genome-tailored therapies priced at curative levels. Believe it or not, the two companies create a natural flywheel: better sequencing data leads to more precise edits, which in turn validates the need for even deeper genomic profiling.
Key Takeaway
When all is said and done, savvy investors don’t have to choose between the read and the edit. Illumina delivers steady, data-driven growth with 4% to 6% revenue expansion guided for 2026 and high-margin consumables. CRISPR Therapeutics offers higher-upside curative potential, already ramping CASGEVY while its pipeline advances.
Undeniably, both face regulatory, reimbursement, and competition risks — China exposure for Illumina, clinical execution for CRISPR. Yet owning the pair gives you the complete personalized biotech stack Cathie Wood has championed for years.
For retail investors seeking direct exposure to the genomics revolution without picking winners in isolation, these two stocks belong together in the portfolio.